Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development. Rapid revenue growth is projected from our leading FDA cleared CellerateRX wound care products, which recent market and clinical validations show to be clinically cost effective with broad uses. CellerateRX has a competitive proprietary feature and performance advantages over other collagen-based products. It is available in powder (95% collagen) and gel (65%) forms that don’t need special handling (like refrigeration). It is active in all 4 phases of wound healing. As CellerateRX revenues grow, the company is positioned to become cash flow positive and profitable in 12-18 months.